ProCE Banner Activity

Oral Treatments for HER2-Negative Early-Stage Breast Cancer: A Guide for Patients and Caregivers

PDF

Download this resource to support patient adherence and persistence to oral anticancer therapies for HER2-negative early-stage breast cancer, including CDK4/6 inhibitors, PARP inhibitors, and endocrine therapy.

Released: June 05, 2024

Expiration: June 04, 2025

Share

Faculty

Julia A LaBarbera

Julia A LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner

Disclosure

Primary Author

Julia A LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

Julia A. LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.